Accelerating Sustainable Practice Change to Improve Evidence-Based Care for Patients With Triple-Negative Breast Cancer

Intended Audience: Community oncologists and their clinical teams, including PAs, NPs, nurses, and pharmacists caring for patients with TNBC

Join us in unraveling the complexities of providing quality triple-negative breast cancer (TNBC) care within community settings. In this expert-led podcast, we'll review insights learned from a recent community-based quality improvement initiative, including top challenges and strategies for improvement in TNBC care.

Tune in for an engaging discussion on the latest clinical evidence, and expert strategies for differentiating and sequencing novel therapies, and mitigating adverse events.

• Evaluate provider- and system-based practices, gaps, and barriers to the integration of novel TNBC therapies in community clinics
• Differentiate novel TNBC therapies based on mechanism of action and the latest clinical trial safety and efficacy data
• Align treatment selection with evidence-based guidelines, patient-, disease-, and/or treatment factors, and appropriate sequencing methods
• Devise interprofessional strategies to optimize clinic processes and patient engagement in community-based healthcare settings

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0.45 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Aditya Bardia, MD, MPH (Course Director, Speaker)
  
  Consultant – Biotheranostics, Daiichi Sankyo/AstraZeneca, Eli Lilly and Company, Genentech, Immunomedics, Merck, Novartis, Pfizer, Phillips, Puma, Radius Health, Sanofi, Taiho Oncology
  Grants / Research Support – Biotheranostics, Daiichi Sankyo/AstraZeneca, Eli Lilly and Company, Genentech, Immunomedics, Merck, Novartis, Pfizer, Phillips, Puma, Radius Health, Sanofi, Taiho Oncology
  The relationships reported above are related to the following therapeutic area: Oncology
• Sara M Tolaney, MD, MPH (Speaker)
  
  Advisory Board or Panel – 4D Pharam, ARC Therapeutics, Aadi Biopharma, AstraZeneca, Bayer, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, CytomX, Daiichi Sankyo, Eisai, Eli Lilly and Company, Ellipses Pharma, Genentech/Roche, Gilead Sciences, Infinity Therapeutics, Menarini/Stemline, Merck, Novartis, OncXerna, OncoPep, OncoSec Medical Inc., Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zetagen, Zymeworks
  Consultant – 4D Pharam, ARC Therapeutics, Aadi Biopharma, AstraZeneca, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, CytomX, Daiichi Sankyo, Eisai, Eli Lilly and Company, Ellipses Pharma, Genentech/Roche, Gilead Sciences, Menarini/Stemline, Merck, Novartis, OncXerna, OncoPep, Pfizer, Sanofi, Seattle Genetics, Zetagen, Zymeworks
  Grants / Research Support – Aadi Biopharma, AstraZeneca, Bristol-Myers Squibb, Cyclacel, Daiichi Sankyo, Eisai, Eli Lilly and Company, Exelixis, Genentech/Roche, Gilead Sciences, Infinity Therapeutics, Merck, Novartis, OncoPep, Pfizer, Sanofi, Seattle Genetics, Umoja Biopharma, Zymeworks
  The relationships reported above are related to the following therapeutic area: Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Kevin O. Hwang, MD, MPH (Reviewer)
• Abimbola Farinde, PhD, PharmD (Planner)
• Joyce M Knestrick, PhD, CRNP, FAANP (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.